In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SilverHawk EXL catheter launched in the US:

This article was originally published in Clinica

Executive Summary

FoxHollow Technologies has launched its SilverHawk EXL plaque excision device in the US. The product is designed to remove atherosclerotic tissue that blocks arteries in the lower leg of patients suffering from peripheral artery disease (PAD). It is an advance on the currently-marketed SilverHawk product line in that it has a lengthened nosecone and includes Redwood City, California-based FoxHollow's micro efficient compression (MEC) technology - laser-drilled micro vent holes in the tip of the catheter. These vents provide more space for the collection of tissue in the tip of the device. It is expected to be CE marked for sale in Europe by the end of this quarter, and will be marketed as part of the firm's integrated commercial effort with Plymouth, Minnesota-based ev3, once the firms' merger closes at the end of this year (see Clinica No 1266, p 3).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel